CBER Director Peter Marks (Susan Walsh/Pool via AP Images)
June 21, 2024 04:00 PM EDTUpdated June 24, 03:40 PM
Pharma
Cell/Gene Tx
FDA+

Pe­ter Marks sin­gle-hand­ed­ly ap­proved Sarep­ta’s gene ther­a­py — what does that mean for every­one else?

Lei Lei Wu

News Reporter

Is Sarep­ta spe­cial? Or has the FDA set a new prece­dent for how it ap­proach­es treat­ments for dev­as­tat­ing dis­eases with few op­tions?

On Thurs­day, the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Car­olyn Bertozzi’s lat­est biotech de­buts with $30M seed round and a sug­ary spin on im­munother­a­py

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times